drugset / Trial / NCT00238446

Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Heart Transplant Recipients

NCT00238446

Phase 3 Completed Novartis Pharmaceuticals
RandomizedSingle-groupOpen-labelPrevention

Summary

This purpose of this extension study of patients being treated with EC-MPS is to assess the long term safety of this medication.

Timeline

Start
2003-04
Primary completion
2006-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Mycophenolate Sodium Unknown

Indications

No indication recorded.